Please wait a minute...
Clinical and Experimental Obstetrics & Gynecology  2020, Vol. 47 Issue (4): 541-545    DOI: 10.31083/j.ceog.2020.04.5484
Original Research Previous articles | Next articles
Mode of delivery does not have a relationship with high-risk HPV positivity
G. Sel1, *(), A. Barut1, Ü. Özmen1, A. Y. Akdemir1, S. Harma2, B. Aynalı1, M. Harma1, M.İ. Harma1
1Zonguldak Bülent Ecevit University, Zonguldak, 67000, Turkey
2Demiroglu Bilim University, İstanbul, 34000, Turkey
Download:  PDF(305KB)  ( 229 ) Full text   ( 9 )
Export:  BibTeX | EndNote (RIS)      

Objective: This study aims to evaluate the delivery room data for patients who give birth with standard vaginal delivery and caesarean section (C/S), to estimate whether high-risk (HR) HPV status affected the mode of delivery. Methods: Between January 2014 and January 2018, 8,376 pregnant women gave birth in our hospital. Of 8,376 patients, 1,039 pregnant women were aged 30 years and older and had HPV results known. They had a singleton pregnancy and no contraindications for standard delivery. Results: C/S rates for all HR HPV groups were lower than for all HPV-negative groups. However, no statistically significant difference was found between HR HPV-positive and HPV-negative patients for C/S rates got all 987 patients (18.75% vs. 24.39%) (p = 0.463), 245 primiparous patients (50.0% vs. 59.83%) (p = 0.629) and 742 multiparous patients (11.53% vs. 12.56%) (p = 0.876). Conclusion: HR HPV positivity does not affect normal vaginal labour progress and does not statistically increase C/S rates at the labour ward. Therefore, HR HPV positivity should not be regarded as a negative risk factor for normal vaginal labour progress.

Key words:  HPV      C/S transition      NSVD      Labour      Delivery      High-risk HPV     
Submitted:  09 January 2020      Accepted:  24 June 2020      Published:  15 August 2020     
*Corresponding Author(s):  G. Sel     E-mail:

Cite this article: 

G. Sel, A. Barut, Ü. Özmen, A. Y. Akdemir, S. Harma, B. Aynalı, M. Harma, M.İ. Harma. Mode of delivery does not have a relationship with high-risk HPV positivity. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(4): 541-545.

URL:     OR

Figure 1.  — Summary of the study groups’ formation

Table 1  — Summary of the study groups, NSVD and C/S rates.
Route of delivery All patients (987 patients) Multiparous (742 patients) Primiparous (245 patients)
Number of cases HR HPV + HPV p Number of cases HR HPV + HPV - p Number of cases HR HPV + HPV - p
NSVD 748 26 722 649 23 626 99 3 96
C/S 239 6 233 93 3 90 146 3 143
C/S Rate (%) 24.21 18.75 24.39 0.463 12.53 11.53 12.56 0.876 59.59 50 59.83 0.629
Count of patients
987 32 955 742 26 716 245 6
[1] Paavonen J., Naud P., Salmerón J., Wheeler C.M., Chow S.N., Apter D., et al.: "Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women". Lancet, 2009, 374, 301-314.
doi: 10.1016/S0140-6736(09)61248-4 pmid: 19586656
[2] Bernard H.U.: "Taxonomy and phylogeny of papillomaviruses: an overview and recent developments". Infect Genet Evol, 2013, 18, 357-361.
doi: 10.1016/j.meegid.2013.03.011
[3] De Villiers E.M., Fauquet C., Broker T.R., Bernard H.U., zur H.: "Class Papillomaviruses". Virology, 2004, 324, 17-27.
doi: 10.1016/j.virol.2004.03.033 pmid: 15183049
[4] Centers for Disease Control and Prevention. Genital HPV Infection Fact Sheet. Human Papillomavirus (HPV). 2018. (25 Jan 2020, date last accessed).
[5] Gultekin M., Zayifoglu K.M., Kucukyildiz I., Dundar S., Boztas G., Semra T.H., et al.: "Initial results of population based cervical cancer screening program using HPV testing in one million Turkish women". Int J Cancer, 2018, 142, 1952-1958.
doi: 10.1002/ijc.31212 pmid: 29235108
[6] Freitas A.C., Mariz F.C., Silva M.A., Jesus A.L.S.: "Human papillomavirus vertical transmissio.: review of current data". Clin Infect Dis, 2013, 56, 1451-1456.
doi: 10.1093/cid/cit066
[7] Lee S.M., Park J.S., Norwitz E.R., Koo J.N., Oh I.H., Park J.W., et al.: "Risk of vertical transmission of human papillomavirus throughout pregnancy: a prospective study". PloS one, 2013, 8, e66368.
doi: 10.1371/journal.pone.0066368 pmid: 23785495
[8] Zuo Z., Goel S., Carter J.E.: "Association of cervical cytology and HPV DNA status during pregnancy with placental abnormalities and preterm birth". Am J Clin Pathol, 2011, 136, 260-265.
doi: 10.1309/AJCP93JMIUEKRPIW
[9] Gomez L.M., Ma Y., Ho C., McGrath C.M., Nelson D.B., Parry S.: "Placental infection with human papillomavirus is associated with spontaneous preterm delivery". Hum Reprod, 2008, 23, 709-715.
doi: 10.1093/humrep/dem404 pmid: 18184644
[10] Cho G., Min K.J., Hong H.R., Kim S., Hong J.H., Lee J.K., et al.: "High-risk human papillomavirus infection is associated with premature rupture of membranes". BMC Pregnancy Childbirth, 2013, 13, 173.
doi: 10.1186/1471-2393-13-173 pmid: 24011340
[11] Hermonat P.L., Kechelava S., Lowery C.L., Korourian S.: "Trophoblasts are the preferential target for human papilloma virus infection in spontaneously aborted products of conception". Hum Pathol, 1998, 29, 170-174.
doi: 10.1016/s0046-8177(98)90228-3 pmid: 9490277
[12] Weinstock H., Berman S., Cates Jr. W.: "Sexually transmitted diseases among American yout.: incidence and prevalence estimates, 2000". Perspect Sex Reprod Health, 2004, 36, 6-10.
doi: 10.1363/psrh.36.6.04 pmid: 14982671
[13] Romero R., Espinoza J., Kusanovic J.P., Gotsch F., Hassan S., Erez O., et al.: "The preterm parturition syndrome". BJOG, 2006, 113, 17-42.
doi: 10.1111/j.1471-0528.2006.00879.x pmid: 16529565
[14] Donati L., Di Vico A., Nucci M., Quagliozzi L., Spagnuolo T., Labianca A., et al.: "Vaginal microbial flora and outcome of pregnancy". Arch Gynecol Obstet, 2010, 281, 589-600.
doi: 10.1007/s00404-009-1318-3
[15] Giakoumelou S., Wheelhouse N., Cuschieri K., Entrican G., Howie S.E., Horne A.W.: "The role of infection in miscarriage". Hum Reprod Update, 2016, 22, 116-133.
doi: 10.1093/humupd/dmv041 pmid: 26386469
[16] Manuck T.A., Esplin M.S., Biggio J., Bukowski R., Parry S., Zhang H., et al.: "The phenotype of spontaneous preterm birth: application of a clinical phenotyping tool". Am J Obstet Gynecol, 2015, 212, 487-e1.
doi: 10.1016/j.ajog.2015.02.010 pmid: 25687564
[17] Niyibizi J., Zanré N., Mayrand M.H., Trottier H.: "The association between adverse pregnancy outcomes and maternal human papillomavirus infectio.: a systematic review protocol". Syst Rev, 2017, 6, 53.
doi: 10.1186/s13643-017-0443-5 pmid: 28284227
[18] Rustveld L.O., Kelsey S.F., Sharma R.: "Association between maternal infections and preeclampsi.: a systematic review of epidemiologic studies". Matern Child Health J, 2008, 12, 223-242.
doi: 10.1007/s10995-007-0224-1 pmid: 17577649
[19] Nimrodi M., Kleitman V., Wainstock T., Gemer O., Meirovitz M., Maymon E., et al.: "The association between cervical inflammation and histologic evidence of HPV in PAP smears and adverse pregnancy outcome in low risk population". Eur J Obstet Gynecol Reprod Biol, 2018, 225, 160-165.
doi: 10.1016/j.ejogrb.2018.04.023 pmid: 29727786
[20] Inal M.M., Köse S., Yildirim Y., Ozdemir Y., Töz E., Ertopçu K., et al.: "The relationship between human papillomavirus infection and cervical intraepithelial neoplasia in Turkish women". Int J Gynecol Cancer., 2007, 17, 1266-1270.
doi: 10.1111/j.1525-1438.2007.00944.x pmid: 17442019
[21] Tuncer Z.S., Basaran M., Ustaçelebi S., Kuzey G.M.: "High-risk human papilloma virus (HPV) infection determined by hybrid capture ii assay in a Turkish University Hospital Outpatient Clinic". Obstet Gynaecol Reprod Med, 2006, 12, 129-134.
[22] Ozçelik B., Serin I.S., Gökahmetoğlu S., Başbuğ M., Erez R.: "Human papillomavirus frequency of women at low risk of developing cervical cance.: a preliminary study from a Turkish University Hospital". Eur J Gynaecol Oncol, 2003, 24, 157-159.
pmid: 12701968
[23] Seçkin S., Aksoy F., Yıldırım M.: "Servikal Smearlerde HPV İnfeksiyonu Görülme İndisansı". Ankara Numune Eğitim ve Araştırma Hastanesi Tıp Dergisi, 1996, 36, 101-103. [In Turkish]
[24] Dursun P., Ayhan A., Mutlu L., Çağlar M., Haberal A., Güngör T., et al.: "HPV types in Turke.: multicenter hospital based evaluation of 6388 patients in Turkish Gynecologic Oncology Group Centers". Turk Patoloji Derg, 2013, 29, 210-216.
doi: 10.5146/tjpath.2013.01188 pmid: 24022311
[25] Kelly R.W.: "Inflammatory mediators and cervical ripening". J Reprod Immunol, 2002, 57, 217-224.
doi: 10.1016/s0165-0378(02)00007-4 pmid: 12385844
[26] Brummer O., Böhmer G., Hollwitz B., Flemming P., Petry K-U., Kühnle HJ.Go.: "MMP-1 and MMP-2 in the cervix uteri in different steps of malignant transformation—an immunohistochemical study". Gynecol Oncol, 2002, 84, 222-227.
doi: 10.1006/gyno.2001.6413
[27] Davidson B., Goldberg I., Kopolovic J., Lerner-Geva L., Gotlieb W.H., Ben-Baruch G., et al.: "MMP-2 and TIMP-2 expression correlates with poor prognosis in cervical carcinoma—a clinicopathological study using immuohistochemistry and mRNA in situ hybridization". Gynecol Oncol, 1999, 73, 372-382.
doi: 10.1006/gyno.1999.5381 pmid: 10366463
[1] I.F. Urunsak, U.K. Gulec, E. Eser, M. Sucu, C. Akcabay, S. Buyukkurt. The role of dinoprostone for labor induction in postterm and high-risk term pregnancies[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(5): 664-668.
[2] S. Srisukho, K. Srisupundit, T. Tongsong. Fulfillment of the criteria for diagnosis of cephalo-pelvic disproportion: ACOG guidelines[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(4): 500-504.
[3] N. Dropińska, K. Chmaj-Wierzchowska, M. Wojciechowska, M. Wilczak. What is the state of knowledge on preterm birth?[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(4): 505-510.
[4] L. Mamas, E. Mamas. Prophylactic cervical cerclage, fully embedded, for twin pregnancies following fertility treatment[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(2): 238-242.
[5] C. Chollet, B. Andre, M. Voglimacci, A. Ghassani, O. Parant, P. Guerby. Perinatal outcomes of second trimester antenatal genital bleeding[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(1): 105-110.
[6] K.-C. Moon, J.-M. Lee, E.-S. Yoon, B.-I. Lee, S.-H. Park. Can pregnancy following muscle-sparing transverse abdominis myocutaneous (MS-TRAM) flaps be safe on abdominal wall?[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(1): 37-40.
[7] L. Andrejevic, A. Andrejevic, V. Nestorovic, B. Milosevic, S. Andrejevic, S. Nestorovic. Multiparty, relation with patology of pregnancy and delivery[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(1): 117-121.
[8] R. Csorba, P. Tsikouras, A. Bothou, S. Zervoudis, G. Iatrakis, X. Anthoulaki, D. Deuteraiou, A. Chalkidou, G. F. von Tempelhoff. Air travel during pregnancy: an update review and practical recommendation[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(6): 862-866.
[9] P. Karlı, F. Z. Özen. A benign disease characterized by vulvar itching: vulvar vestibular papillomatosis[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(6): 969-971.
[10] M. Aslam, Areej Ghormulla Alghamdi, Nawal G. Alghamdi, Khushnoor Khan. Monitoring and assessing pre-labor obstetric practicesc using control charts: cesarean delivery cases[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(4): 570-574.
[11] I. Pimentel-Soares, A. C. Sartorato Beleza, M. da Silva Corrêa, M. Vieira Batistão, P. Driusso. Long-term effect of first childbirth on pelvic floor muscle function: cross-sectional study[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(4): 630-634.
[12] R. Rzepka, B. Dołęgowska, N. Marczuk, S. Kwiatkowski, A. Rajewska, K. Nurek, A. Torbè. Novel inflammatory markers of labor following premature preterm rupture of membranes[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(3): 359-367.
[13] L. Wang, N. Zhao, J. Zhou, M. Xu. Factors for predicting cesarean section during epidural analgesia: a retrospective study[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(3): 443-446.
[14] N. Yachida, M. Itsukaichi, K. Haino, T. Usuda, J. Yoshimura, T. Enomoto, M. Yamaguchi, K. Takakuwa. Influence of route of delivery on perinatal outcomes in fetuses with myelomeningocele[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(2): 277-279.
[15] J.H. Check, D.L. Check, R. Chern. Successful live delivery despite an inappropriate rise in the serial human chorionic gonadotropin level[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(2): 297-298.
No Suggested Reading articles found!